SAN CLEMENTE, CA—Daniel Woolson, Vice President and General Manager of Infusion Capital at ICU Medical Inc. (NASDAQ:ICUI), a medical device company with a market capitalization of $3.82 billion, recently made a significant transaction involving the company's stock. The sale comes as InvestingPro data shows the stock has gained over 56% year-to-date, though technical indicators suggest the stock is currently in oversold territory. On December 6, Woolson sold 2,241 shares of ICU Medical (TASE:PMCN)'s common stock at a price of $156.251 per share, totaling approximately $350,158. Following this transaction, Woolson retains ownership of 10,866 shares in the company. The transaction was executed at the exact price disclosed, as noted in the filing. The company maintains a strong financial position, with InvestingPro reporting a "GOOD" overall financial health score and liquid assets exceeding short-term obligations. For deeper insights into insider transactions and comprehensive financial analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, ICU Medical Inc. and Becton Dickinson (NYSE:BDX) (BD) have seen recent developments that could interest investors. KeyBanc Capital Markets maintained an overweight rating on ICU Medical shares, following a survey on infusion pumps indicating potential market share gains for the company. ICU Medical was ranked second in vendor preference, capturing about 28% of customer selection. A recent joint venture agreement for IV Solutions has led KeyBanc to adjust its EBITDA estimate for ICU Medical by a $25 million reduction.
On the earnings front, ICU Medical reported a revenue of $580 million for the third quarter of 2024, a 7% increase on a constant currency basis. The company also highlighted strong demand across all regions and growth in its consumables and IV Systems segments. Adjusted EBITDA stood at $95 million, and the company raised its future guidance, with adjusted EBITDA expected to be between $355 million to $365 million.
In parallel, Becton Dickinson reported a 7.4% growth in Q4 revenue and a 5% full-year organic revenue increase. Adjusted diluted earnings per share also rose by 11.4%, reaching $13.14 for the full year. The company announced a $1 billion share repurchase plan and increased its dividend by 9.5%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.